

Supporting Information

Enantioselective Access to Spirooxindole δ -lactones and Acyclic 3, 3'-Disubstituted Oxindole-Derivatives by N-heterocyclic Carbene Catalysts

Xiaomei Wang^a, Weixing Zeng^a, Shi-Wu Li^{a*}, Jixin Pian^b, Zhifei Zhao^{a*}

a. School of Chemistry and Chemical Engineering/State Key Laboratory Incubation Base for Green Processing of Chemical Engineering, Shihezi University, Shihezi, Xinjiang 832003, China.

b. School of Pharmacy, Xinjiang Second Medical College, Karamay, Xinjiang Uygur Autonomous Region, 834000, People's Republic of China.

Table of Contents

I	General Information	S1
II	X-ray crystallographic analysis	S1
III	Experimental Section	S2
IV	General procedure for [3+3] cycloaddition reaction	S5
V	Procedures for derivatizations of products	S5
VI	Reference	S7
VII	Characterizations of new compounds	S7
VIII	NMR Spectrum	S25
IX	Chiral HPLC analysis trace	S67

I. General Information

Commercially available materials were used as received, unless otherwise noted, all reactions and manipulations involving air- or moisture-sensitive compounds were performed using standard Schlenk technique. Reactions were checked by TLC analysis and plates were visualized with short-wave UV light (254 nm). The ¹H, ¹³C NMR and ¹⁹F spectra were obtained in CDCl₃ using a Bruker-BioSpin AVANCE III HD NMR spectrometer at 400 MHz, 100 MHz and 376 MHz respectively. Chemical shifts are reported in parts per million (δ value) calibrated against the residual solvent peak. HPLC analysis of the compounds was done using chiralcel IC column using hexane and isopropanol as eluent, and the column temperature is 40 °C. The Rudolph Autopol V polarimeter was employed to gauge the optical rotation. The melting point was measured by Shanghai Instrument electrooptical SGW X-4A micro melting point instrument. High resolution mass spectra(HRMS) were recorded on Thermo Scientific Q Exactive mass spectrometry equipped with an APCI source. Crystal structure data was collected on a SuperNova, Dual, Cu at zero, Atlas diffractometer. The following abbreviations are used to designate chemical shift multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet.

II. X-ray crystallographic analysis

CCDC 2407944 (**3bc**) suitable for X-ray crystallography was obtained by crystallization via evaporation from its hexane/DCM solution.




Figure 1. X-Ray crystallographic data of **3bc**

CCDC 2407944 (**3bc**) contain the supplementary crystallographic data for this paper. These data are provided free of charge by The Cambridge Crystallographic Data Centre.

Table 1. Crystal data and structure refinement for **3bc**


Identification code	3bc
Empirical formula	C ₃₀ H ₂₅ NO ₇
Formula weight	511.51
Temperature	173.0 K
Wavelength	1.54178
Crystal system	Monoclinic

Space group	P2 ₁	
Unit cell dimensions	a = 9.0595(3) b = 9.2127(3) c = 15.4455(5)	a= 90 b= 102.057(2) g = 90
Volume	1260.68(7) ³	
Z	2	
Density (calculated)	1.347 Mg/m ³	
Absorption coefficient	0.796 mm ⁻¹	
F(000)	536	
Crystal size	0.14 × 0.12 ×0.11 mm ³	
Theta range for data collection	4.992 to 72.052	
Index ranges	-10<=h<=11, -11<=k<=11, -19<=l<=18	
Reflections collected	16713	
Independent reflections	4871 [R(int) = 0.0426]	
Completeness to theta	99.7 %	
Absorption correction	Semi-empirical from equivalents	
Max. and min. transmission	0.7536 and 0.6778	
Refinement method	Full-matrix least-squares on F ²	
Data / restraints / parameters	4871 / 1 / 345	
Goodness-of-fit on F ²	1.044	
Final R indices [I>2sigma(I)]	R1 = 0.0344, wR2 = 0.0785	
R indices (all data)	R1 = 0.0387, wR2 = 0.0811	
Absolute structure parameter	-0.03(9)	
Extinction coefficient	n/a	
Largest diff. peak and hole	0.233 and -0.163 e. ⁻³	


III. Experimental Section

1. General procedure for the synthesis of indole-enal


1. Substrates 1a-1m are known compounds and were prepared according to the literature reports.^[1-2]



2. Substrates **1a** and **1n** were synthesized according to the following procedure:




To a solution of isatin **1** (2.0 mmol) in DMF (10 mL) was added potassium carbonate (3.0 mmol) followed by **2** (2.4 mmol). The mixture was stirred for 2 h at room temperature (the progress of the reaction was monitored by TLC). After completion of the reaction the mixture was diluted with cold water (50 mL) followed by EtOAc (50 mL) and stirred for 10 min. The organic layer separated was collected and the aqueous layer was extracted with additional EtOAc (2×50 mL). The organic layers were collected, combined, dried over anhydrous Na₂SO₄, filtered and concentrated under vacuo. The residue was purified by column chromatography on silica gel using hexane/ethyl acetate to afford the desired product **3**.




To a solution of N-protected isatin (1.0 equiv, 10 mmol) in THF (0.5 M) were added DBU (10 mol %) and acetaldehyde (3.0 equiv), and the reaction mixture was kept at -25 °C for 15 h. After completion of the reaction, the mixture was kept at room temperature and a 3:1 mixture of AcOH/H₂O (10 mL) and a few drops of conc. H₂SO₄ were added. This mixture was then refluxed for 30 min in an oil bath. The reaction mixture was diluted with water, extracted with dichloromethane, and washed with water followed by brine. The organic layer was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude was purified by silica column chromatography using petroleum ether/ethyl acetate mixture as eluent (90:10, v/v) to obtain compounds 5.

2. General procedure for the synthesis of ethyl 2,4-oxo-4-R-butanoate

1. Substrates **2a-2o** are known compounds and were prepared according to the literature reports.^[3]




2. Substrates **2a** and **2o** were synthesized according to the following procedure:




To sodium hydride (2.0 equiv) in DMF (0.5 M) was added drop wise in ice cold condition under nitrogen atmosphere. Then **1** (1.0 equiv, 10 mmol) was added and stirred for 30 min at room temperature. Finally diethyl oxalate **2** (3.0 equiv) was added and the reaction mixture was again stirred for 3h at room temperature. The completion of the reaction was monitored by TLC and quenched with crushed ice. Then the reaction mixture was extracted with ethyl acetate (2×100 mL), washed with

water (150 mL) and brine solution (150 mL). The organic layer was separated, dried over anhydrous sodium sulphate and evaporation of solvent afforded the expected product **3**

IV. General procedure for [3+3] cycloaddition reaction




Compound **1** (0.10 mmol) and compound **2** (0.15 mmol), ^tBuOK (50 mol%), NHC precursor (10 mol%), DQ (120 mol%) and were added to 15 mL Schlenk tube, after vacuum replacement of argon, THF (1 mL) was added to this solution at room temperature, and the mixture was stirred for 3 h. Following the completion of the reaction (monitored using TLC), the raw product underwent direct flash column chromatography on silica gel (200-300 mesh, PE/EA v/v = 3:1 as the eluent) to produce the respective products **3**.



Compound **3** (0.1 mmol) was added to 15 ml pressure-resistant tube, MeOH (1 mL) was added to this solution at 80 °C and the mixture was stirred for 15 h. Following the completion of the reaction (monitored using TLC), the raw product underwent direct flash column chromatography on silica gel (200-300 mesh, PE/EA v/v = 4:1 as the eluent) to produce the respective products **4**.


V. Procedures for derivatizations of products

1.




Compound **4aa** (41 mg, 1.0 equiv) was added to 15 mL Schlenk tube, after vacuum replacement of argon, MeOH (1 mL) was added to this solution at 0 °C. NaBH₄ (15.2 mg, 4.0 equiv) is added to the mixed solution of **4aa** in MeOH. The mixture was allowed to stir at this temperature for further 2 h, with its progression being observed using TLC. Following the completion of the reaction, saturated solution of H₂O (2 mL) was added and the aqueous phase was extracted with ethyl acetate (5 mL×3). The combined extracts were dried by Na₂SO₄. After the removal of solvent, purification by flash column chromatography (hexane/ethyl acetate = 3:1) was carried out to give pure product **5a** (colorless oil, 31 mg, 86 % yield, 93 % ee, dr > 20:1).

2.



To a solution of the suitable alcohol, **4bj** (0.1 mmol) in dry DCM (1 mL), and cooled to 0 C, was added, portion-wise and drop-wise, 4-dimethylaminopyridine (0.01 mmol), p-toluenesulfonyl chloride (1.2 mmol) and triethylamine (0.05 mmol). The reaction mixture was stirred at 0 °C until TLC showed complete consumption of starting material. The resulting suspension was diluted with diethyl ether (2 mL), stirred for a further 30 min, and the precipitate removed by filtration. The solution was then washed sequentially with water (3 mL), 10% NaHCO₃ (2 x 3 mL) and a saturated aqueous NaCl solution (2 mL). The combined organic layers were dried over Na₂SO₄, filtered, The solution was directly purified by silica gel column chromatography (hexane/ethyl acetate = 3:1) to afford **6a** (white solid, 31 mg, 90% yield, 94% ee).

3.




Methyltriphenylphosphonium bromide (143 mg, 0.4 mmol, 4.0 equiv) was suspended in freshly distilled THF (1 mL) and cooled to -78 °C. n-BuLi (0.4 mmol, 4.0 equiv) was added in batches and the resulting solution was stirred for 1 h. The resulting solution was then stirred while warming to room temperature for 1 h. and then reaction was cooled to -78 °C. **4aa** (0.1 mmol, 1.0 equiv) was added. The resulting solution was then stirred while warming to room temperature for 15 h. The solution was directly purified by silica gel column chromatography (hexane/ethyl acetate = 3:1) to afford **7a** (colorless oil, 36 mg, 90% yield, 92% ee).

VI. Reference:


- [1] R.K Kumar; Y. Sreenivas; S. Sandhya; K. Ajit; M. Parimal; B. Rao; P. Manojit. Ultrasound-based approach to spiro-2,3-dihydroquinazolin-4(1H)-ones: their in vitro evaluation against chorismate mutase. *Tetrahedron Letters.*, **2013**, *54*, 495–501.
- [2] T. Vivekanand, B.S. Vachan, M. Karuppasamy, I. Muthukrishnan, U. Maheswari, S. Nagarajan, N. Bhuvanesh, V. Sridharan, Diastereoselective ABB' Three-Component Synthesis of Highly Functionalized Spirooxindoles Bearing Five Consecutive Asymmetric Carbons, *J. Org. Chem.*, **2019**, *84*, 4009-4016.
- [3]. S. Rajendran; B. Govindharasu; K. Maruthan; A. Jayachitra; Padmini, V. Multiple biological activities and molecular docking studies of newly synthesized 3-(pyridin-4-yl)-1H-pyrazole-5-carboxamide chalcone hybrids, *Bioorg. Med. Chem. Lett.*, **2016**, *26*, 5624-5630.

VII. Characterizations of new compounds




Ethyl-(R)-5'-benzoyl-1-benzyl-2,2'-dioxo-2',3'-dihydrospiro[indoline-3,4'-pyran]-6'-carboxylate (3aa): Orange solid (38 mg, 79 % yield). Mp: 66.1–71.6 °C. HPLC:


91% ee (Chiralpak IC column, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, tr (major) = 30.003 min, tr (minor) = 26.149 min. $[\alpha]_D^{20} = +14.3$ ($c = 0.2$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ : 7.72 (d, $J = 9.7$ Hz, 2H), 7.55–7.49 (m, 1H), 7.41–7.32 (m, 3H), 7.25 (d, $J = 2.0$ Hz, 2H), 7.18 (d, $J = 9.0$ Hz, 2H), 7.15–7.10 (m, 3H), 7.01–6.96 (m, 1H), 6.58 (d, $J = 7.9$ Hz, 1H), 4.76 (q, $J = 15.7$ Hz, 2H), 4.02 (dd, $J = 7.1, 5.3$ Hz, 2H), 3.10 (d, $J = 3.2$ Hz, 2H), 1.03 (t, $J = 7.1$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ : 190.9, 174.3, 163.2, 159.6, 143.6, 142.3, 136.2, 134.6, 133.7, 129.9, 128.8, 128.6, 127.8, 127.1, 126.5, 124.7, 124.3, 123.5, 110.1, 62.7, 50.3, 44.3, 36.6, 13.4. HRMS (APCI) m/z calcd for $\text{C}_{29}\text{H}_{24}\text{NO}_6^+$ ($\text{M}+\text{H}$)⁺ 482.1598, found 482.1578.



Ethyl(R)-5'-benzoyl-1-methyl-2,2'-dioxo-2',3'-dihydrospiro[indoline-3,4'-pyran]-6'-carboxylate (3ab): Yellow solid (34 mg, 85 % yield). Mp: 64.7–68.9 °C. HPLC: 93% ee (Chiralpak IC column, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, tr (major) = 70.609 min, tr (minor) = 38.824 min. $[\alpha]_D^{20} = +23.6$ ($c = 0.2$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ : 7.75–7.73 (m, 1H), 7.57–7.49 (m, 1H), 7.43–7.33 (m, 2H), 7.28–7.23 (m, 4H), 7.15–7.06 (m, 2H), 6.96 (d, $J = 10.0$ Hz, 2H), 6.47 (d, $J = 8.0$ Hz, 1H), 4.89–4.61 (m, 2H), 4.18–3.83 (m, 2H), 3.29–2.89 (m, 2H), 2.21 (s, 3H), 1.02 (t, $J = 7.1$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ : 191.2, 175.4, 163.4, 159.8, 143.9, 140.6, 136.8, 136.6, 134.0, 133.7, 129.0, 128.9, 128.7, 127.5, 127.4, 125.6, 124.8, 123.7, 122.2, 120.9, 62.8, 50.1, 45.7, 37.3, 18.7, 13.5. HRMS (APCI) m/z calcd for $\text{C}_{23}\text{H}_{20}\text{NO}_6^+$ ($\text{M}+\text{H}$)⁺ 406.1285, found 406.1240




Ethyl(R)-5'-benzoyl-1-ethyl-2,2'-dioxo-2',3'-dihydrospiro[indoline-3,4'-pyran]-6'-carboxylate (3ac): Orange oil (41mg, 98 % yield). HPLC: 93% ee (Chiralpak IC column, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, tr (major) = 41.648 min, tr (minor) = 32.954 min. $[\alpha]_D^{20} = +145.6$ ($c = 0.2$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ : 7.65 (d, $J = 7.0$ Hz, 2H), 7.51–7.46 (m, 1H), 7.38–7.31 (m, 2H), 7.24 (s, 1H), 7.18 (d, $J = 7.6$ Hz, 1H), 7.06–6.99 (m, 1H), 6.71 (d, $J = 7.9$ Hz, 1H), 4.03 (tq, $J = 7.2, 3.7$ Hz, 2H), 3.67–3.49 (m, 2H), 3.04 (s, 2H), 1.05 (dt, $J = 11.9, 7.2$ Hz, 6H). ^{13}C NMR (100 MHz, CDCl_3) δ : 191.0, 173.8, 163.5, 143.5, 142.4, 136.3, 133.7, 130.1, 128.8, 128.6, 126.7, 124.7, 123.4, 109.1, 62.8, 50.2, 36.2, 35.3, 13.6, 12.3. HRMS (APCI) m/z calcd for $\text{C}_{24}\text{H}_{22}\text{NO}_6^+$ ($\text{M}+\text{H}$)⁺ 420.1442, found 420.1444




3ad

Ethyl-(*R*)-5'-benzoyl-1-benzyl-7-methyl-2,2'-dioxo-2',3'-dihydrospiro[indoline-3,4'-pyran]-6'-carboxylate (3ad): Brown soild (45 mg, 92 % yield). Mp 67.8–70.1 °C HPLC: 84 % ee (Chiralpak IC column, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, tr (major) = 26.941 min, tr (minor) = 30.908 min. $[\alpha]_D^{20} = +43.6$ ($c = 0.2$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ : 7.75–7.73 (m, 1H), 7.57–7.49 (m, 1H), 7.43–7.33 (m, 2H), 7.28–7.23 (m, 4H), 7.15–7.06 (m, 2H), 6.96 (d, $J = 10.0$ Hz, 2H), 6.47 (d, $J = 8.0$ Hz, 1H), 4.89–4.61 (m, 2H), 4.18–3.83 (m, 2H), 3.29–2.89 (m, 2H), 2.21 (s, 3H), 1.02 (t, $J = 7.1$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ : 191.2, 175.4, 163.4, 159.8, 143.9, 140.6, 136.8, 136.6, 134.0, 133.7, 129.0, 128.9, 128.7, 127.5, 127.4, 125.6, 124.8, 123.7, 122.2, 120.9, 62.8, 50.1, 45.7, 37.3, 18.7, 13.5. HRMS (APCI) m/z calcd for $\text{C}_{30}\text{H}_{26}\text{NO}_6^+$ ($\text{M}+\text{H}$)⁺ 496.1755, found 496.1720.




Ethyl(*R*)-5'-benzoyl-1-benzyl-5,6-difluoro-2,2'-dioxo-2',3'-dihydrospiro[indoline-3,4'-pyran]-6'-carboxylate (3ba): Orange soild (49 mg, 96 % yield). Mp 76.4–77.8 °C, HPLC: 82 % ee (Chiralpak IC column, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, tr (major) = 34.268 min, tr (minor) = 31.813 min. $[\alpha]_D^{20} = +20.6$ ($c = 0.2$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ : 7.64 (s, 1H), 7.34 (s, 1H), 7.25 (dd, $J = 7.0, 3.5$ Hz, 4H), 7.18 (d, $J = 8.1$ Hz, 1H), 7.15 (d, $J = 8.2$ Hz, 2H), 7.11 (d, $J = 3.6$ Hz, 2H), 7.02–6.95 (m, 1H), 6.58 (d, $J = 7.9$ Hz, 1H), 4.85 (d, $J = 15.8$ Hz, 1H), 4.70 (d, $J = 15.7$ Hz, 1H), 4.03 (dq, $J = 7.2, 3.5$ Hz, 2H), 3.08 (d, $J = 1.3$ Hz, 1H), 3.00 (d, $J = 13.5$ Hz, 1H), 2.37 (s, 3H), 1.03 (t, $J = 7.1$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ : 190.4, 174.2, 163.3, 159.7, 144.7, 143.2, 142.3, 134.6, 133.8, 129.9, 129.4, 129.0, 128.9, 128.8, 127.7, 127.1, 126.6, 124.9, 124.4, 123.5, 110.0, 62.6, 50.4, 44.3, 36.7, 21.7, 13.5. HRMS (APCI) m/z calcd for $\text{C}_{29}\text{H}_{22}\text{F}_2\text{NO}_6^+$ ($\text{M}+\text{H}$)⁺ 518.1410, found 518.1417.




Ethyl(*R*)-1-benzyl-5'-(4-(tert-butyl)benzoyl)-2,2'-dioxo-2',3'-dihydrospiro[indolin-3,4'-pyran]-6'-carboxylate (3bb): Red oil (28 mg, 53 % yield). HPLC: 88 % ee

(Chiralpak IC column, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, tr (major) = 28.197 min, tr (minor) = 22.209 min. $[\alpha]_D^{20} = -27.1$ ($c = 0.2$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ : 7.68 (d, $J = 8.5$ Hz, 2H), 7.39 (d, $J = 8.5$ Hz, 2H), 7.25 (d, $J = 9.4$ Hz, 3H), 7.19–7.12 (m, 4H), 6.96 (d, $J = 6.7$ Hz, 1H), 6.57 (d, $J = 7.8$ Hz, 1H), 4.77 (s, 2H), 3.98 (dd, $J = 7.1, 3.0$ Hz, 2H), 3.77 (s, 1H), 3.10 (d, $J = 2.5$ Hz, 2H), 1.30 (s, 9H), 0.96 (t, $J = 7.1$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ : 190.6, 174.4, 163.4, 159.7, 157.6, 143.7, 142.3, 134.7, 133.9, 129.9, 128.8, 128.7, 127.7, 127.1, 126.8, 125.6, 124.7, 124.2, 123.5, 110.1, 62.6, 50.5, 44.3, 36.6, 35.2, 31.0, 13.3. HRMS (APCI) m/z calcd for $\text{C}_{33}\text{H}_{32}\text{NO}_6^+(\text{M}+\text{H})^+$ 538.2224, found 538.2216.




Ethyl(R)-1-benzyl-5'-(4-methoxybenzoyl)-2,2'-dioxo-2',3'-dihydrospiro[indoline-3,4'-pyran]-6'-carboxylate (3bc): Orange solid (48 mg, 94 % yield). Mp 85.7–87.4 °C, HPLC: 93 % ee (Chiralpak IC column, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, tr (major) = 71.310 min, tr (minor) = 62.655 min. $[\alpha]_D^{20} = +5.8$ ($c = 0.2$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ : 7.71 (d, $J = 8.9$ Hz, 2H), 7.26–7.21 (m, 3H), 7.20 (d, $J = 6.3$ Hz, 1H), 7.17–7.12 (m, 1H), 7.07 (dd, $J = 6.8, 2.8$ Hz, 2H), 7.02–6.96 (m, 1H), 6.83 (d, $J = 8.9$ Hz, 2H), 6.58 (d, $J = 7.9$ Hz, 1H), 4.88 (d, $J = 15.8$ Hz, 1H), 4.70 (d, $J = 15.8$ Hz, 1H), 4.10–4.01 (m, 2H), 3.82 (s, 3H), 3.08 (s, 2H), 1.05 (t, $J = 7.2$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ : 189.2, 174.3, 164.1, 163.4, 159.7, 142.9, 142.3, 134.6, 131.2, 129.9, 129.3, 128.8, 127.7, 127.0, 126.5, 125.1, 124.5, 123.5, 113.9, 110.0, 62.6, 55.5, 50.4, 44.3, 36.7, 13.5. HRMS (APCI) m/z calcd for $\text{C}_{30}\text{H}_{26}\text{NO}_7^+(\text{M}+\text{H})^+$ 512.1704, found 512.1697.




Ethyl(R)-1-benzyl-5'-(2,3-dihydrobenzo[b][1,4]dioxine-6-carbonyl)-2,2'-dioxo-2',3'-dihydrospiro[indoline-3,4'-pyran]-6'-carboxylate (3bd): Orange solid (53 mg, 98 % yield). Mp 60.3–63.4 °C, HPLC: 87 % ee (Chiralpak IC column, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, tr (major) = 59.493 min, tr (minor) = 53.766 min. $[\alpha]_D^{20} = -91.0$ ($c = 0.2$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ : 7.33–7.26 (m, 3H), 7.25 (s, 2H), 7.20–7.09 (m, 4H), 7.02–6.96 (m, 1H), 6.81 (d, $J = 8.2$ Hz, 1H), 6.59 (d, $J = 7.8$ Hz, 1H), 4.92 (d, $J = 15.8$ Hz, 1H), 4.71 (d, $J = 15.8$ Hz, 1H), 4.30–4.17 (m, 4H), 4.13–4.02 (m, 2H), 3.16–2.98 (m, 2H), 1.08 (t, $J = 7.1$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ : 189.2, 174.3, 163.5, 159.8, 148.8, 143.6, 143.1, 142.4, 134.8, 130.2, 130.0, 128.9, 127.8, 127.2, 126.7, 125.0, 124.5, 123.6, 123.3, 118.2, 117.5, 110.2, 64.8, 64.0, 62.7, 50.5, 44.4, 36.8, 13.7. HRMS (APCI) m/z calcd for $\text{C}_{33}\text{H}_{32}\text{NO}_6^+(\text{M}+\text{H})^+$ 538.2224, found 538.2216.


for $C_{31}H_{26}INO_8^+(M+H)^+$ 540.1653 , found 540.1644.



Ethyl(R)-1-benzyl-5'-(3,4-dichlorobenzoyl)-2,2'-dioxo-2',3'-dihydrospiro[indoline-3,4'-pyran]-6'-carboxylate (3be): Yellow soild (36 mg, 66 % yield). Mp 57.9–59.0 °C. HPLC: 90 % ee (Chiralpak IC column, 254 nm, hexane/isopropanol = 90:10, flow rate 0.3 mL/min, tr (major) = 242.538 min, tr (minor) = 234.514 min. $[\alpha]_D^{20} = +4.8$ ($c = 0.2$, CH_2Cl_2). 1H NMR (400 MHz, $CDCl_3$) δ : 7.79 (d, $J = 2.0$ Hz, 1H), 7.54 (dd, $J = 8.4, 2.0$ Hz, 1H), 7.39 (d, $J = 8.4$ Hz, 1H), 7.26 (d, $J = 6.4$ Hz, 3H), 7.19 (d, $J = 6.1$ Hz, 2H), 7.12–7.08 (m, 2H), 7.06–6.99 (m, 1H), 6.66 (d, $J = 8.1$ Hz, 1H), 4.89 (d, $J = 33.6$ Hz, 1H), 4.70 (d, $J = 15.7$ Hz, 1H), 4.12 (t, $J = 7.2$ Hz, 2H), 3.10 (d, $J = 8.2$ Hz, 1H), 3.00 (d, $J = 14.0$ Hz, 1H), 1.15 (t, $J = 7.2$ Hz, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ : 188.6, 173.9, 162.9, 159.5, 143.5, 142.2, 138.2, 135.6, 134.4, 133.4, 130.7, 130.2, 128.8, 127.9, 127.8, 127.1, 126.1, 124.4, 124.2, 123.7, 110.1, 62.9, 50.3, 44.3, 36.4, 13.6. HRMS (APCI) m/z calcd for $C_{29}H_{21}Cl_2NO_6^+$ ($M+H$)⁺ 550.0819, found 550.0823.




Ethyl(R)-5'-(2-naphthoyl)-1-benzyl-2,2'-dioxo-2',3'-dihydrospiro[indoline-3,4'-pyran]-6'-carboxylate (3bf): Orange soild (36 mg, 66 % yield). Mp 69.1–75.1 °C. HPLC: 93 % ee (Chiralpak IC column, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, tr (major) = 33.1038 min, tr (minor) = 29.683 min. $[\alpha]_D^{20} = +23.7$ ($c = 0.2$, CH_2Cl_2). 1H NMR (400 MHz, $CDCl_3$) δ : 8.26 (s, 1H), 7.90 (d, $J = 8.1$ Hz, 1H), 7.84 (d, $J = 7.6$ Hz, 1H), 7.77 (d, $J = 5.4$ Hz, 1H), 7.60 (d, $J = 8.1$ Hz, 1H), 7.56–7.50 (m, 2H), 7.24 (d, $J = 7.4$ Hz, 1H), 7.11 (d, $J = 7.9$ Hz, 2H), 7.08–7.04 (m, 2H), 7.01–6.96 (m, 3H), 6.51 (d, $J = 7.8$ Hz, 1H), 4.77–4.61 (m, 2H), 4.05–3.95 (m, 2H), 3.00 (d, $J = 13.3$ Hz, 3H), 0.99 (t, $J = 7.1$ Hz, 3H). ^{13}C NMR (100 MHz, $CDCl_3$) δ : 190.7, 174.3, 163.3, 159.7, 143.7, 142.3, 135.8, 134.5, 133.6, 132.3, 131.3, 129.9, 129.8, 129.0, 128.8, 128.7, 128.7, 127.8, 127.7, 127.0, 126.9, 126.4, 125.0, 124.5, 123.7, 123.6, 110.1, 62.7, 62.0, 50.4, 44.3, 37.1, 36.7, 34.1, 14.0, 13.5, 13.6. HRMS (APCI) m/z calcd for $C_{33}H_{26}NO_6^+$ ($M+H$)⁺ 532.1755, found 532.1749.




Methyl(R)-2-(1-benzyl-2-oxo-3-(2-oxo-2-phenylethyl)indolin-3-yl)acetate (4aa):

White solid (40 mg, 98 % yield). Mp: 63.2–65.3 °C. HPLC: 92% ee (Chiralpak IC column, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, tr (major) = 15.043 min, tr (minor) = 10.932 min. $[\alpha]_D^{20} = +19.5$ ($c = 0.2$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ : 7.87 (d, $J = 7.1$ Hz, 2H), 7.56–7.50 (m, 1H), 7.45 (d, $J = 6.8$ Hz, 2H), 7.44–7.39 (m, 2H), 7.38–7.30 (m, 3H), 7.28 (d, $J = 7.3$ Hz, 1H), 7.17–7.11 (m, 1H), 6.96–6.90 (m, 1H), 6.74 (d, $J = 8.6$ Hz, 1H), 5.14–4.84 (m, 2H), 4.11 (d, $J = 17.8$ Hz, 1H), 3.61 (d, $J = 17.8$ Hz, 1H), 3.54 (s, 3H), 3.16 (d, $J = 15.8$ Hz, 1H), 2.84 (d, $J = 15.8$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ : 195.8, 179.1, 170.3, 143.5, 136.46, 136.1, 133.3, 130.6, 128.7, 128.5, 128.3, 128.0, 127.4, 127.4, 123.6, 122.3, 109.3, 51.7, 47.1, 44.3, 41.1. HRMS (APCI) m/z calcd for $\text{C}_{26}\text{H}_{24}\text{NO}_4^+$ ($\text{M}+\text{H}$)⁺ 414.1700, found 414.1692.




Methyl(R)-2-(1-methyl-2-oxo-3-(2-oxo-2-phenylethyl)indolin-3-yl)acetate. Brown oil (37 mg, 98 % yield). HPLC: 93% ee (Chiralpak IC column, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, tr (major) = 16.774 min, tr (minor) = 14.502 min. $[\alpha]_D^{20} = +14.2$ ($c = 0.2$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ : 7.83 (d, $J = 7.0$ Hz, 2H), 7.54–7.49 (m, 1H), 7.42–7.37 (m, 2H), 7.32 (d, $J = 8.7$ Hz, 1H), 7.27 (d, $J = 11.1$ Hz, 1H), 6.99–6.94 (m, 1H), 6.89 (d, $J = 7.8$ Hz, 1H), 4.05 (d, $J = 17.9$ Hz, 1H), 3.56–3.51 (m, 4H), 3.31 (s, 3H), 3.12 (d, $J = 16.0$ Hz, 1H), 2.79 (d, $J = 15.9$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ : 196.0, 179.1, 170.5, 144.5, 136.5, 133.38, 130.73, 128.6, 128.5, 128.0, 123.6, 122.3, 108.3, 51.8, 47.1, 44.4, 40.9, 26.69. HRMS (APCI) m/z calcd for $\text{C}_{27}\text{H}_{26}\text{NO}_4^+$ ($\text{M}+\text{H}$)⁺ 428.1856, found 428.1848.




Methyl(R)-2-(1-methyl-2-oxo-3-(2-oxo-2-phenylethyl)indolin-3-yl)acetate (4ac):

Brown oil (33 mg, 95 % yield). HPLC: 93% ee (Chiralpak IC column, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, tr (major) = 69.544 min, tr (minor)


= 67.201 min. $[\alpha]_D^{20} = +27.3$ ($c = 0.2$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ : 7.84 (d, $J = 7.0$ Hz, 2H), 7.54–7.49 (m, 1H), 7.43–7.35 (m, 2H), 7.33 (d, $J = 7.5$ Hz, 1H), 7.26 (d, $J = 7.8$ Hz, 1H), 6.98–6.93 (m, 1H), 6.91 (d, $J = 7.8$ Hz, 1H), 4.03 (d, $J = 17.8$ Hz, 1H), 3.85 (q, $J = 7.2$ Hz, 2H), 3.52 (d, $J = 16.6$ Hz, 4H), 3.12 (d, $J = 15.9$ Hz, 1H), 2.79 (d, $J = 15.8$ Hz, 1H), 1.35 (t, $J = 7.2$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ : 195.9, 178.6, 170.5, 143.6, 136.6, 133.3, 130.9, 128.6, 128.4, 128.1, 123.9, 122.1, 108.4, 51.7, 47.1, 44.4, 41.0, 35.0, 12.3. HRMS (APCI) m/z calcd for $\text{C}_{21}\text{H}_{22}\text{NO}_4^+$ ($\text{M}+\text{H}$)⁺ 352.1543, found 352.1539.




Methyl(R)-2-(1-allyl-2-oxo-3-(2-oxo-2-phenylethyl)indolin-3-yl)acetate (4ad): Brown oil (34 mg, 94 % yield). HPLC: 94 % ee (Chiralpak IC column, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, tr (major) = 12.238 min, tr (minor) = 10.921 min. $[\alpha]_D^{20} = +12.3$ ($c = 0.2$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ : 7.84 (d, $J = 8.3$ Hz, 2H), 7.55–7.47 (m, 1H), 7.43–7.37 (m, 2H), 7.32 (d, $J = 7.4$ Hz, 1H), 7.26–7.20 (m, 1H), 6.99–6.92 (m, 1H), 6.89 (d, $J = 7.7$ Hz, 1H), 5.95 (ddd, $J = 22.5, 10.4, 5.3$ Hz, 1H), 5.43 (d, $J = 17.2$ Hz, 1H), 5.28 (d, $J = 10.4$ Hz, 1H), 4.44 (s, 2H), 4.07 (d, $J = 17.9$ Hz, 1H), 3.62–3.52 (m, 4H), 3.13 (d, $J = 15.9$ Hz, 1H), 2.80 (d, $J = 15.9$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ : 195.8, 178.7, 170.3, 143.6, 136.4, 133.2, 131.7, 130.6, 128.5, 128.3, 128.0, 123.5, 122.2, 117.6, 109.1, 51.7, 47.0, 44.4, 42.81, 41.0. HRMS (APCI) m/z calcd for $\text{C}_{22}\text{H}_{22}\text{NO}_4^+$ ($\text{M}+\text{H}$)⁺ 364.1543, found 364.1537.




Methyl(R)-2-(2-oxo-3-(2-oxo-2-phenylethyl)-1-(prop-2-yn-1-yl)indolin-3-yl)acetate (4ae): Brown oil (33 mg, 92 % yield). HPLC: 93 % ee (Chiralpak IC column, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, tr (major) = 14.419 min, tr (minor) = 11.351 min. $[\alpha]_D^{20} = +31.3$ ($c = 0.2$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ : 7.83 (d, $J = 7.1$ Hz, 2H), 7.56–7.45 (m, 1H), 7.41 (d, $J = 8.1$ Hz, 2H), 7.34 (d, $J = 7.5$ Hz, 1H), 7.33–7.27 (m, 1H), 7.12 (d, $J = 7.8$ Hz, 1H), 7.04–6.97 (m, 1H), 4.72 (d, $J = 20.3$ Hz, 1H), 4.51 (d, $J = 20.2$ Hz, 1H), 4.06 (d, $J = 17.9$ Hz, 1H), 3.55 (d, $J = 17.9$ Hz, 4H), 3.14 (d, $J = 15.9$ Hz, 1H), 2.83 (d, $J = 15.9$ Hz, 1H), 2.29 (t, $J = 2.5$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ : 195.9, 178.2, 170.4, 142.7, 136.4, 133.4, 130.5, 128.6, 128.6, 128.1, 123.8, 122.8, 109.3, 72.3, 51.9, 47.1, 44.5, 41.0, 29.8. 41.0. HRMS (APCI) m/z calcd for $\text{C}_{22}\text{H}_{20}\text{NO}_4^+$ ($\text{M}+\text{H}$)⁺ 362.1387, found 362.1380.



Methyl(R)-2-(1-benzyl-7-methyl-2-oxo-3-(2-oxo-2-phenylethyl)indolin-3-yl)acetate (4af): Brown oil (40 mg, 94 % yield). HPLC: 93 % ee (Chiralpak IC column, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, tr (major) = 14.502 min, tr (minor) = 16.774 min. $[\alpha]_D^{20} = +15.3$ ($c = 0.2$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ : 7.88 (d, $J = 7.1$ Hz, 2H), 7.56–7.51 (m, 1H), 7.43 (q, $J = 7.7$ Hz, 4H), 7.37–7.33 (m, 2H), 7.28 (d, $J = 7.3$ Hz, 1H), 7.13 (s, 1H), 6.93 (d, $J = 7.9$ Hz, 1H), 6.62 (d, $J = 7.9$ Hz, 1H), 5.07–4.94 (m, 2H), 4.09 (d, $J = 17.9$ Hz, 1H), 3.63 (s, 1H), 3.55 (s, 3H), 3.14 (d, $J = 15.8$ Hz, 1H), 2.84 (d, $J = 15.8$ Hz, 1H), 2.22 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ : 195.9, 179.1, 170.5, 141.2, 136.6, 136.3, 133.3, 131.8, 130.8, 128.8, 128.7, 128.7, 128.6, 128.2, 127.5, 124.5, 109.1, 51.8, 47.3, 44.4, 41.2, 21.2. HRMS (APCI) m/z calcd for $\text{C}_{27}\text{H}_{26}\text{NO}_4^+$ ($\text{M}+\text{H}$)⁺ 428.1856, found 428.1848.




Methyl(R)-2-(1-benzyl-5,7-dimethyl-2-oxo-3-(2-oxo-2-phenylethyl)indolin-3-yl)acetate (4ag): Brown oil (43 mg, 97 % yield). HPLC: 91 % ee (Chiralpak IC column, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, tr (major) = 30.006 min, tr (minor) = 13.907 min. $[\alpha]_D^{20} = +26.3$ ($c = 0.2$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ : 7.89 (d, $J = 9.8$ Hz, 2H), 7.58–7.49 (m, 1H), 7.46–7.30 (m, 6H), 7.30–7.23 (m, 1H), 6.95 (s, 1H), 6.73 (s, 1H), 5.23 (s, 2H), 4.09 (d, $J = 17.8$ Hz, 1H), 3.64 (d, $J = 32.4$ Hz, 4H), 3.08 (d, $J = 15.6$ Hz, 1H), 2.83 (d, $J = 15.6$ Hz, 1H), 2.21 (d, $J = 19.2$ Hz, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ : 195.9, 179.9, 170.4, 139.2, 138.4, 136.5, 133.2, 132.9, 131.7, 131.6, 128.7, 128.5, 128.1, 126.9, 126.0, 121.8, 119.4, 51.7, 46.6, 45.6, 44.5, 41.7, 20.8, 18.7. HRMS (APCI) m/z calcd for $\text{C}_{28}\text{H}_{28}\text{NO}_4^+$ ($\text{M}+\text{H}$)⁺ 442.2013, found 442.2006.




Methyl(R)-2-(1-benzyl-5-methoxy-2-oxo-3-(2-oxo-2-phenylethyl)indolin-3-yl)acetate (4ah): Brown oil (43 mg, 98 % yield). HPLC: 94 % ee (Chiralpak IC column, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, tr (major) = 18.126 min, tr (minor) = 13.642 min. $[\alpha]_D^{20} = +27.8$ ($c = 0.2$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ : 7.88 (d, $J = 8.2$ Hz, 1H), 7.58–7.50 (m, 1H), 7.42 (q, $J = 7.6, 7.1$ Hz, 3H), 7.38–7.31 (m, 2H), 7.28 (d, $J = 7.3$ Hz, 1H), 7.21 (d, $J = 8.2$ Hz, 1H), 7.10–6.99 (m, 1H), 6.97 (d,

J = 2.4 Hz, 1H), 6.93 (s, 1H), 6.65–6.62 (m, 1H), 5.08–4.92 (m, 2H), 4.10 (d, *J* = 17.9 Hz, 1H), 3.76 (d, *J* = 2.8 Hz, 1H), 3.65 (d, *J* = 24.1 Hz, 3H), 3.57 (d, *J* = 4.6 Hz, 3H), 3.16 (d, *J* = 16.0 Hz, 1H), 2.83 (d, *J* = 16.0 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ: 195.8, 178.7, 170.3, 155.6, 136.4, 136.1, 133.3, 128.7, 128.5, 128.0, 127.4, 127.4, 112.3, 111.4, 109.5, 56.0, 55.6, 51.7, 47.5, 44.4, 44.3, 41.0. HRMS (APCI) m/z calcd for C₂₇H₂₆NO₅⁺ (M+H)⁺ 444.1805, found 444.1798.




4ai

Methyl-(R)-2-(1-benzyl-5-fluoro-2-oxo-3-(2-oxo-2-phenylethyl)indolin-3-yl)acetate (4ai): Brown oil (42 mg, 97 % yield). HPLC: 91 % ee (Chiralpak IC column, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, tr (major) = 10.721 min, tr (minor) = 8.186 min. [α]_D²⁰ = +13.1 (c = 0.2, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ: 7.89 (d, *J* = 8.3 Hz, 2H), 7.55 (d, *J* = 14.8 Hz, 1H), 7.44 (d, *J* = 7.6 Hz, 4H), 7.40–7.33 (m, 2H), 7.30 (d, *J* = 7.2 Hz, 1H), 7.15 (dd, *J* = 8.2, 2.6 Hz, 1H), 6.88–6.78 (m, 1H), 6.64 (dd, *J* = 8.6, 4.2 Hz, 1H), 5.01 (q, *J* = 15.9 Hz, 2H), 4.13 (d, *J* = 18.0 Hz, 1H), 3.60 (d, *J* = 18.1 Hz, 4H), 3.19 (d, *J* = 16.2 Hz, 1H), 2.83 (d, *J* = 16.2 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ: 195.7, 179.0, 170.3, 160.2, 157.8, 139.6, 139.6, 136.3, 135.9, 133.5, 132.5, 132.4, 128.9, 128.7, 128.1, 127.7, 127.4, 114.7, 114.4, 112.4, 112.1, 109.8, 109.8, 51.9, 47.6, 47.6, 44.5, 44.4, 40.9. ¹⁹F NMR (376 MHz, CDCl₃) δ -120.64. HRMS (APCI) m/z calcd for C₂₆H₂₃FNO₄⁺ (M+H)⁺ 432.1606, found 432.1600.




4aj

Methyl-(R)-2-(1-benzyl-5-chloro-2-oxo-3-(2-oxo-2-phenylethyl)indolin-3-yl)acetate (4aj) : Brown oil (43 mg, 97 % yield). HPLC: 93 % ee (Chiralpak IC column, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, tr (major) = 9.806 min, tr (minor) = 7.722 min. [α]_D²⁰ = -15.9 (c = 0.2, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ: 7.89 (d, *J* = 8.2 Hz, 2H), 7.58–7.52 (m, 1H), 7.46–7.40 (m, 4H), 7.35 (d, *J* = 7.0 Hz, 3H), 7.31 (s, 1H), 7.11 (dd, *J* = 8.3, 2.1 Hz, 1H), 6.65 (d, *J* = 8.3 Hz, 1H), 5.07–4.95 (m, 2H), 4.12 (d, *J* = 18.1 Hz, 1H), 3.61 (d, *J* = 21.1 Hz, 4H), 3.16 (d, *J* = 16.2 Hz, 1H), 2.82 (d, *J* = 16.1 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ: 195.6, 178.8, 170.2, 142.4, 136.2, 135.7, 133.6, 132.6, 128.9, 128.7, 128.3, 128.1, 127.8, 127.7, 127.4, 124.3, 110.3, 51.9, 47.3, 44.5, 44.5, 41.0. HRMS (APCI) m/z calcd for C₂₆H₂₃ClNO₄⁺ (M+H)⁺ 448.1310, found 448.1304.




4ak

Methyl(R)-2-(1-benzyl-5-bromo-2-oxo-3-(2-oxo-2-phenylethyl)indolin-3-yl)acetat e (4ak): Brown oil (48 mg, 98 % yield). HPLC: 87 % ee (Chiralpak IC column, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, tr (major) = 9.931 min, tr (minor) = 7.822 min. $[\alpha]_D^{20} = +17.4$ ($c = 0.2$, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ : 7.88 (d, $J = 7.2$ Hz, 2H), 7.58–7.53 (m, 1H), 7.47–7.42 (m, 4H), 7.37 (d, $J = 7.3$ Hz, 2H), 7.30 (d, $J = 7.2$ Hz, 3H), 6.60 (d, $J = 8.3$ Hz, 1H), 5.06–4.95 (m, 2H), 4.11 (d, $J = 18.1$ Hz, 1H), 3.61 (d, $J = 20.3$ Hz, 4H), 3.15 (d, $J = 16.2$ Hz, 1H), 2.81 (d, $J = 16.2$ Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ : 195.6, 178.7, 170.2, 142.9, 136.2, 135.7, 133.6, 133.0, 131.3, 128.9, 128.7, 128.2, 127.7, 127.4, 127.0, 115.2, 110.8, 52.0, 47.3, 44.5, 41.1. HRMS (APCI) m/z calcd for C₂₆H₂₃BrNO₄⁺ (M+H)⁺ 492.0805, found 492.0797.



4al


Methyl(R)-2-(1-benzyl-7-bromo-2-oxo-3-(2-oxo-2-phenylethyl)indolin-3-yl)acetat e (4al): Brown oil (45 mg, 93 % yield). HPLC: 93 % ee (Chiralpak IC column, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, tr (major) = 17.729 min, tr (minor) = 8.951 min. $[\alpha]_D^{20} = -19.4$ ($c = 0.2$, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ : 7.87 (d, $J = 7.1$ Hz, 2H), 7.58–7.52 (m, 1H), 7.47–7.39 (m, 4H), 7.37–7.32 (m, 3H), 7.27 (d, $J = 8.6$ Hz, 2H), 6.86–6.79 (m, 1H), 5.47 (d, $J = 5.4$ Hz, 2H), 4.10 (d, $J = 15.0$ Hz, 1H), 3.65 (d, $J = 17.9$ Hz, 1H), 3.59 (s, 3H), 3.11 (d, $J = 15.9$ Hz, 1H), 2.83 (d, $J = 15.9$ Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ : 195.6, 180.0, 170.2, 141.3, 138.2, 136.3, 134.5, 134.2, 133.6, 128.7, 128.5, 128.1, 126.9, 126.7, 126.4, 123.6, 122.5, 102.6, 51.9, 46.8, 45.3, 44.6, 41.5. HRMS (APCI) m/z calcd for C₂₆H₂₃BrNO₄⁺ (M+H)⁺ 492.0805, found 492.0796.




4am

Methyl(R)-2-(1-benzyl-6-chloro-2-oxo-3-(2-oxo-2-phenylethyl)indolin-3-yl)acetat e (4am): Brown oil (44 mg, 98 % yield). HPLC: 91 % ee (Chiralpak IC column, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, tr (major) = 9.946 min, tr (minor) = 7.787 min. $[\alpha]_D^{20} = +13.5$ ($c = 0.2$, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ :


7.89 (d, $J = 8.3$ Hz, 2H), 7.58–7.53 (m, 1H), 7.47–7.41 (m, 4H), 7.38–7.34 (m, 3H), 7.30 (d, $J = 7.2$ Hz, 1H), 7.11 (dd, $J = 8.3, 2.2$ Hz, 1H), 6.65 (d, $J = 8.4$ Hz, 1H), 5.07–4.95 (m, 2H), 4.12 (d, $J = 18.0$ Hz, 1H), 3.61 (d, $J = 21.2$ Hz, 4H), 3.16 (d, $J = 16.2$ Hz, 1H), 2.82 (d, $J = 16.2$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ : 195.6, 178.8, 170.2, 142.4, 136.2, 135.7, 133.6, 132.6, 128.9, 128.7, 128.3, 128.1, 127.8, 127.7, 127.4, 124.3, 110.3, 51.9, 47.3, 44.5, 44.5, 41.0. HRMS (APCI) m/z calcd for $\text{C}_{26}\text{H}_{23}\text{ClNO}_4^+$ ($\text{M}+\text{H}$)⁺ 448.1310, found 448.1304.




Methyl(R)-2-(1-benzyl-2-oxo-3-(2-oxo-2-phenylethyl)indolin-3-yl)acetate (4an): Brown oil (40 mg, 97 % yield). HPLC: 80 % ee (Chiralpak IC column, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, tr (major) = 7.851 min, tr (minor) = 6.671 min. $[\alpha]_D^{20} = +19.4$ (c = 0.2, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ : 7.88 (d, $J = 7.5$ Hz, 2H), 7.55 (d, $J = 6.4$ Hz, 1H), 7.46–7.35 (m, 6H), 7.30 (d, $J = 9.1$ Hz, 2H), 6.57–6.51 (m, 1H), 4.97 (q, $J = 15.8$ Hz, 2H), 4.10 (d, $J = 18.0$ Hz, 1H), 3.57 (d, $J = 19.8$ Hz, 4H), 3.18 (d, $J = 16.4$ Hz, 1H), 2.80 (d, $J = 16.4$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ : 195.7, 179.1, 170.2, 136.2, 135.4, 133.7, 129.0, 128.8, 128.1, 127.9, 127.5, 114.1, 113.9, 99.7, 99.5, 52.0, 47.2, 44.7, 44.4, 40.9. ^{19}F NMR (376 MHz, CDCl_3) δ : -136.6, -145.9. HRMS (APCI) m/z calcd for $\text{C}_{26}\text{H}_{22}\text{F}_2\text{NO}_4^+$ ($\text{M}+\text{H}$)⁺ 450.1511, found 450.1505.




Methyl (R)-2-(1-benzyl-2-oxo-3-(2-oxo-2-(p-tolyl)ethyl)indolin-3-yl)acetate (4ba): Brown oil (42 mg, 98 % yield). HPLC: 90 % ee (Chiralpak IC column, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, tr (major) = 17.838 min, tr (minor) = 12.811 min. $[\alpha]_D^{20} = +12.4$ (c = 0.2, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ : 7.77 (d, $J = 8.0$ Hz, 2H), 7.45 (d, $J = 7.6$ Hz, 2H), 7.34 (q, $J = 7.4$ Hz, 3H), 7.28 (d, $J = 7.0$ Hz, 1H), 7.20 (d, $J = 7.9$ Hz, 2H), 7.16–7.10 (m, 1H), 6.92 (t, $J = 7.5$ Hz, 1H), 6.73 (d, $J = 7.8$ Hz, 1H), 5.17–4.83 (m, 2H), 4.07 (d, $J = 17.7$ Hz, 1H), 3.56 (d, $J = 24.0$ Hz, 4H), 3.16 (d, $J = 15.8$ Hz, 1H), 2.84 (d, $J = 15.8$ Hz, 1H), 2.38 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ : 195.5, 179.3, 170.5, 144.2, 143.7, 136.3, 134.1, 130.8, 129.3, 128.8, 128.4, 128.3, 127.5, 123.7, 122.4, 109.4, 51.8, 47.3, 44.4, 44.3, 41.2, 21.7. HRMS (APCI) m/z calcd for $\text{C}_{30}\text{H}_{26}\text{NO}_7^+$ ($\text{M}+\text{H}$)⁺ 496.1755, found 496.1767.



Methyl(R)-2-(1-benzyl-3-(2-(4-(tert-butyl)phenyl)-2-oxoethyl)-2-oxoindolin-3-yl)acetate (4bb): Brown oil (46 mg, 93 % yield). HPLC: 88 % ee (Chiralpak IC column, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, tr (major) = 15.511 min, tr (minor) = 10.143 min. $[\alpha]_D^{20} = +17.2$ ($c = 0.2$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ : 7.73 (d, $J = 8.5$ Hz, 2H), 7.35 (dd, $J = 12.0, 8.0$ Hz, 4H), 7.28–7.22 (m, 3H), 7.19 (d, $J = 7.3$ Hz, 1H), 7.07–7.00 (m, 1H), 6.86–6.79 (m, 1H), 6.65 (d, $J = 7.8$ Hz, 1H), 5.01–4.83 (m, 2H), 3.99 (d, $J = 17.8$ Hz, 1H), 3.47 (d, $J = 31.6$ Hz, 4H), 3.09 (d, $J = 15.8$ Hz, 1H), 2.77 (d, $J = 15.8$ Hz, 1H), 1.23 (s, 9H); ^{13}C NMR (100 MHz, CDCl_3) δ : 195.5, 179.2, 170.4, 157.1, 143.6, 136.2, 134.0, 130.8, 128.8, 128.3, 128.1, 127.5, 127.5, 125.5, 123.6, 122.3, 109.3, 51.7, 47.2, 44.4, 41.2, 35.1, 31.1. HRMS (APCI) m/z calcd for $\text{C}_{30}\text{H}_{32}\text{NO}_4^+ (\text{M}+\text{H})^+$ 470.2326, found 470.2319.




Methyl(R)-2-(1-benzyl-3-(2-(4-methoxyphenyl)-2-oxoethyl)-2-oxoindolin-3-yl)acetate (4bc): Brown oil (42 mg, 96 % yield). HPLC: 93 % ee (Chiralpak IC column, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, tr (major) = 26.717 min, tr (minor) = 17.829 min. $[\alpha]_D^{20} = +20.6$ ($c = 0.2$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ : 7.85 (d, $J = 8.9$ Hz, 2H), 7.44 (d, $J = 7.2$ Hz, 2H), 7.39–7.30 (m, 3H), 7.28 (d, $J = 8.5$ Hz, 1H), 7.17–7.09 (m, 1H), 6.96–6.90 (m, 1H), 6.88 (d, $J = 8.9$ Hz, 2H), 6.73 (d, $J = 7.8$ Hz, 1H), 5.22–4.85 (m, 2H), 4.04 (d, $J = 17.5$ Hz, 1H), 3.84 (s, 3H), 3.53 (s, 3H), 3.19–2.82 (m, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ : 194.3, 179.3, 170.5, 163.7, 143.7, 136.3, 130.9, 130.5, 129.7, 128.9, 128.8, 128.4, 127.5, 127.5, 123.7, 122.3, 113.8, 109.4, 55.6, 51.8, 47.3, 44.4, 44.1, 41.2. HRMS (APCI) m/z calcd for $\text{C}_{27}\text{H}_{26}\text{NO}_5^+ (\text{M}+\text{H})^+$ 444.1805 , found 444.1802.




Methyl(R)-2-(1-benzyl-3-(2-(2-methoxyphenyl)-2-oxoethyl)-2-oxoindolin-3-yl)acetate (4bd): Brown oil (41 mg, 92 % yield). HPLC: 94 % ee (Chiralpak IC column, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, tr (major) = 22.445 min, tr (minor) = 19.155 min. $[\alpha]_D^{20} = +12.4$ ($c = 0.2$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3)

δ : 7.52–7.46 (m, 2H), 7.45–7.38 (m, 1H), 7.34 (d, J = 7.6 Hz, 2H), 7.28 (d, J = 8.5 Hz, 2H), 7.19–7.06 (m, 2H), 6.97–6.87 (m, 3H), 6.71 (d, J = 7.8 Hz, 1H), 5.09–4.92 (m, 2H), 4.04 (d, J = 18.1 Hz, 1H), 3.89 (s, 3H), 3.61 (d, J = 18.1 Hz, 1H), 3.49 (s, 3H), 3.17–2.86 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ : 197.8, 179.4, 170.4, 158.7, 143.8, 136.4, 133.9, 131.0, 130.5, 128.8, 128.2, 127.7, 127.6, 127.5, 123.6, 122.2, 120.7, 111.6, 109.2, 55.6, 51.7, 49.8, 47.6, 44.4, 41.3. HRMS (APCI) m/z calcd for $\text{C}_{27}\text{H}_{26}\text{NO}_5^+$ ($\text{M}+\text{H})^+$ 444.1805, found 444.1802.




Methyl(R)-2-(1-benzyl-3-(2-(3-methoxyphenyl)-2-oxoethyl)-2-oxoindolin-3-yl)acetate (4be): Brown oil (42 mg, 94 % yield). HPLC: 88 % ee (Chiralpak IC column, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, tr (major) = 19.184 min, tr (minor) = 13.412 min. $[\alpha]_D^{20} = +19.3$ ($c = 0.2$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ : 7.46 (dd, J = 13.6, 7.8 Hz, 3H), 7.36 (d, J = 9.4 Hz, 3H), 7.32 (d, J = 7.8 Hz, 2H), 7.28 (d, J = 7.3 Hz, 1H), 7.15 (d, J = 7.8 Hz, 1H), 7.08 (dd, J = 8.2, 3.6 Hz, 1H), 6.96–6.90 (m, 1H), 6.75 (d, J = 7.8 Hz, 1H), 5.13–4.91 (m, 2H), 4.09 (d, J = 17.8 Hz, 1H), 3.80 (s, 3H), 3.60 (d, J = 17.8 Hz, 1H), 3.53 (s, 3H), 3.15 (d, J = 15.8 Hz, 1H), 2.84 (d, J = 15.8 Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ : 195.8, 179.2, 170.4, 159.8, 143.7, 137.9, 136.2, 130.7, 129.6, 128.8, 128.4, 127.6, 127.5, 123.7, 122.4, 120.9, 120.1, 112.1, 109.4, 55.5, 51.8, 47.3, 44.6, 44.4, 41.3. HRMS (APCI) m/z calcd for $\text{C}_{27}\text{H}_{26}\text{NO}_5^+$ ($\text{M}+\text{H})^+$ 444.1805, found 444.1802.




Methyl(R)-2-(1-benzyl-3-(2-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-oxoethyl)-2-oxoindolin-3-yl)acetate (4bf): Brown oil (46 mg, 97 % yield). HPLC: 88 % ee (Chiralpak IC column, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, tr (major) = 34.989 min, tr (minor) = 24.496 min. $[\alpha]_D^{20} = -83.2$ ($c = 0.2$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ : 7.45 (d, J = 5.3 Hz, 2H), 7.43–7.35 (m, 3H), 7.32 (d, J = 4.4 Hz, 1H), 7.31–7.27 (m, 2H), 7.12 (d, J = 7.8 Hz, 1H), 6.95–6.89 (m, 1H), 6.85 (d, J = 9.1 Hz, 1H), 6.73 (d, J = 7.8 Hz, 1H), 5.02 (q, J = 15.8 Hz, 2H), 4.30–4.27 (m, 2H), 4.26–4.23 (m, 2H), 4.01 (d, J = 17.7 Hz, 1H), 3.52 (s, 4H), 3.15 (d, J = 15.9 Hz, 1H), 2.83 (d, J = 15.8 Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ : 194.1, 179.2, 170.3, 148.1, 143.5, 143.2, 136.1, 130.7, 130.3, 128.8, 128.7, 128.2, 127.4, 127.4, 123.5, 122.2, 117.6, 117.1, 109.2, 64.6, 64.0, 51.6, 47.2, 44.3, 44.0, 41.1. HRMS (APCI) m/z

calcd for $C_{28}H_{26}NO_6^+$ ($M+H$)⁺ 472.1755, found 472.1748.




Methyl(R)-2-(1-benzyl-3-(2-(4-chlorophenyl)-2-oxoethyl)-2-oxoindolin-3-yl)acetate (4bg): Brown oil (44 mg, 98 % yield). HPLC: 80 % ee (Chiralpak IC column, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, tr (major) = 13.907 min, tr (minor) = 9.754 min. $[\alpha]_D^{20} = +6.7$ (c = 0.2, CH_2Cl_2). 1H NMR (400 MHz, $CDCl_3$) δ : 7.81 (d, $J = 8.6$ Hz, 2H), 7.45 (d, $J = 6.7$ Hz, 2H), 7.40–7.35 (m, 3H), 7.31 (dd, $J = 12.3, 3.6$ Hz, 3H), 7.14 (d, $J = 7.7$ Hz, 1H), 6.94 (s, 1H), 6.75 (d, $J = 7.9$ Hz, 1H), 5.01 (q, $J = 15.8$ Hz, 2H), 4.10 (d, $J = 17.8$ Hz, 1H), 3.58 (d, $J = 24.9$ Hz, 4H), 3.12 (d, $J = 15.9$ Hz, 1H), 2.82 (d, $J = 15.8$ Hz, 1H), ^{13}C NMR (100 MHz, $CDCl_3$) δ : 194.7, 179.0, 170.4, 143.6, 139.9, 136.1, 134.8, 130.6, 129.6, 129.6, 128.9, 128.9, 128.8, 128.5, 127.6, 127.5, 123.6, 122.4, 109.4, 51.8, 47.2, 44.4, 44.2, 41.2. HRMS (APCI) m/z calcd for $C_{23}H_{23}ClNO_2^+$ ($M+H$)⁺ 448.1310 , found 448.1304.



4bh


Methyl(R)-2-(1-benzyl-3-(2-(3-chlorophenyl)-2-oxoethyl)-2-oxoindolin-3-yl)acetate (4bh): Brown oil (42 mg, 94 % yield). HPLC: 94 % ee (Chiralpak IC column, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, tr (major) = 22.629 min, tr (minor) = 9.137 min. $[\alpha]_D^{20} = +9.7$ (c = 0.2, CH_2Cl_2). 1H NMR (400 MHz, $CDCl_3$) δ : 7.81 (d, $J = 8.6$ Hz, 2H), 7.45 (d, $J = 6.7$ Hz, 2H), 7.40–7.35 (m, 3H), 7.31 (dd, $J = 12.3, 3.6$ Hz, 3H), 7.14 (d, $J = 7.7$ Hz, 1H), 6.94 (s, 1H), 6.75 (d, $J = 7.9$ Hz, 1H), 5.01 (q, $J = 15.8$ Hz, 2H), 4.10 (d, $J = 17.8$ Hz, 1H), 3.58 (d, $J = 24.9$ Hz, 4H), 3.12 (d, $J = 15.9$ Hz, 1H), 2.82 (d, $J = 15.8$ Hz, 1H); ^{13}C NMR (100 MHz, $CDCl_3$) δ : 194.7, 179.0, 170.4, 143.6, 139.9, 136.1, 134.8, 130.6, 129.6, 129.6, 128.9, 128.9, 128.8, 128.5, 127.6, 127.5, 123.6, 122.4, 109.4, 51.8, 47.2, 44.4, 44.2, 41.2.. HRMS (APCI) m/z calcd for $C_{23}H_{23}ClNO_2^+$ ($M+H$)⁺ 448.1310, found 448.1304.



4bi


Methyl(R)-2-(1-benzyl-3-(2-(2-iodophenyl)-2-oxoethyl)-2-oxoindolin-3-yl)acetate

(4bi): Brown oil (48 mg, 90 % yield). HPLC: 91 % ee (Chiralpak IC column, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, tr (major) = 15.064 min, tr (minor) = 10.944 min. $[\alpha]_D^{20} = -8.5$ ($c = 0.2$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ : 7.87 (d, $J = 9.7$ Hz, 2H), 7.52 (d, $J = 6.1$ Hz, 1H), 7.44 (d, $J = 5.0$ Hz, 2H), 7.41 (s, 1H), 7.37–7.31 (m, 3H), 7.28 (d, $J = 5.8$ Hz, 1H), 7.17–7.11 (m, 1H), 6.96–6.90 (m, 1H), 6.74 (d, $J = 7.8$ Hz, 1H), 5.11–4.94 (m, 2H), 4.11 (d, $J = 17.8$ Hz, 1H), 3.61 (d, $J = 17.9$ Hz, 1H), 3.54 (s, 3H), 3.16 (d, $J = 15.9$ Hz, 1H), 2.84 (d, $J = 15.8$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ : 195.8, 179.1, 170.3, 143.5, 136.4, 136.1, 133.3, 130.6, 128.7, 128.5, 128.3, 128.0, 127.4, 127.4, 123.6, 122.3, 109.3, 51.7, 47.1, 44.3, 41.1. HRMS (APCI) m/z calcd for $\text{C}_{26}\text{H}_{23}\text{INO}_4^+$ ($\text{M}+\text{H}$) $^+$ 540.0666, found 540.0661.



4bj


Methyl(R)-2-(1-benzyl-3-(2-(5-chloro-2-hydroxyphenyl)-2-oxoethyl)-2-oxoindolin-3-yl)acetate (4bj): Brown oil (43 mg, 92 % yield). HPLC: 86 % ee (Chiralpak IC column, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, tr (major) = 31.288 min, tr (minor) = 26.050 min. $[\alpha]_D^{20} = +17.2$ ($c = 0.2$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ 11.58 (s, 1H), 7.86 (d, $J = 2.4$ Hz, 1H), 7.51 (dd, $J = 8.9, 2.4$ Hz, 1H), 7.43 (d, $J = 9.7$ Hz, 2H), 7.38–7.27 (m, 6H), 7.21–7.15 (m, 2H), 6.99–6.93 (m, 1H), 6.81 (d, $J = 8.9$ Hz, 2H), 5.00 (d, $J = 2.9$ Hz, 2H), 4.18 (d, $J = 18.0$ Hz, 1H), 3.63 (d, $J = 38.8$ Hz, 4H), 3.06 (d, $J = 15.9$ Hz, 1H), 2.79 (d, $J = 15.9$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ : 201.1, 178.7, 170.3, 161.3, 143.6, 139.4, 135.9, 132.1, 130.2, 128.8, 128.7, 127.7, 127.7, 127.4, 123.5, 122.5, 120.7, 120.3, 110.7, 109.5, 51.9, 47.0, 44.4, 43.7, 41.5.; HRMS (APCI) m/z calcd for $\text{C}_{26}\text{H}_{23}\text{ClNO}_5^+$ ($\text{M}+\text{H}$) $^+$ 464.1259, found 464.1071.



4bk


Methyl(R)-2-(1-benzyl-3-(2-(5-bromo-2-hydroxyphenyl)-2-oxoethyl)-2-oxoindolin-3-yl)acetate (4bk): Brown oil (47 mg, 93 % yield). HPLC: 92 % ee (Chiralpak IC column, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, tr (major) = 30.289 min, tr (minor) = 26.471 min. $[\alpha]_D^{20} = +23.7$ ($c = 0.2$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ : 11.58 (s, 1H), 7.86 (d, $J = 2.4$ Hz, 1H), 7.51 (dd, $J = 8.9, 2.4$ Hz, 1H), 7.43 (d, $J = 6.9$ Hz, 2H), 7.34 (s, 2H), 7.29 (dd, $J = 6.7, 3.8$ Hz, 2H), 7.17 (d, $J = 7.8$ Hz, 1H), 6.99–6.93 (m, 1H), 6.83–6.77 (m, 2H), 5.00 (d, $J = 2.9$ Hz, 2H), 4.18 (d, $J = 18.0$ Hz, 1H), 3.65 (d, $J = 18.0$ Hz, 1H), 3.58 (s, 3H), 3.06 (d, $J = 15.9$ Hz, 1H), 2.79

(d, $J = 15.9$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ : 201.0, 178.5, 170.1, 161.2, 143.5, 139.3, 135.8, 132.0, 130.1, 128.7, 128.5, 127.6, 127.6, 123.4, 122.4, 120.6; 120.2, 110.5, 109.4, 51.8, 46.8, 44.3, 43.6, 41.3. HRMS (APCI) m/z calcd for $\text{C}_{26}\text{H}_{23}\text{BrNO}_5^+$ ($\text{M}+\text{H}$) $^+$ 508.0754, found 508.0750.




4bl

Methyl(R)-2-(1-benzyl-3-(2-(3,4-dichlorophenyl)-2-oxoethyl)-2-oxoindolin-3-yl)acetate (4bl): Brown oil (47 mg, 98 % yield). HPLC: 85 % ee (Chiralpak IC column, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, tr (major) = 13.817 min, tr (minor) = 9.785 min. $[\alpha]_D^{20} = +6.3$ (c = 0.2, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ : 7.94 (d, $J = 2.0$ Hz, 1H), 7.69 (dd, $J = 8.4, 2.1$ Hz, 1H), 7.49 (d, $J = 8.4$ Hz, 1H), 7.47–7.40 (m, 2H), 7.39–7.32 (m, 2H), 7.32–7.27 (m, 2H), 7.19–7.11 (m, 1H), 6.94 (t, $J = 7.6$ Hz, 1H), 6.75 (d, $J = 7.8$ Hz, 1H), 5.12–4.92 (m, 2H), 4.09 (d, $J = 17.9$ Hz, 1H), 3.58 (d, $J = 14.4$ Hz, 4H), 3.09 (d, $J = 15.9$ Hz, 1H), 2.81 (d, $J = 15.9$ Hz, 1H), ^{13}C NMR (100 MHz, CDCl_3) δ : 193.8, 178.8, 170.4, 143.6, 138.1, 136.0, 136.0, 133.4, 130.8, 130.4, 130.2, 128.9, 128.6, 127.7, 127.5, 127.2, 123.6, 122.5, 109.5, 51.9, 47.2, 44.4, 44.2, 41.2. HRMS (APCI) m/z calcd for $\text{C}_{26}\text{H}_{21}\text{Cl}_2\text{NO}_4^+$ ($\text{M}+\text{H}$) $^+$ 482.0920, found 482.0914.




4bm

Methyl(R)-2-(1-benzyl-3-(2-(naphthalen-2-yl)-2-oxoethyl)-2-oxoindolin-3-yl)acetate (4bm): Orange oil (41 mg, 90 % yield). HPLC: 89 % ee (Chiralpak IC column, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, tr (major) = 18.221 min, tr (minor) = 13.396 min. $[\alpha]_D^{20} = +19.4$ (c = 0.2, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ : 8.43 (s, 1H), 7.91 (d, $J = 8.6$ Hz, 2H), 7.87–7.82 (m, 2H), 7.61–7.53 (m, 2H), 7.47 (d, $J = 8.6$ Hz, 2H), 7.41–7.32 (m, 3H), 7.29 (d, $J = 8.6$ Hz, 1H), 7.18–7.11 (m, 1H), 6.98–6.89 (m, 1H), 6.76 (d, $J = 7.8$ Hz, 1H), 5.04 (d, $J = 24.9$ Hz, 2H), 4.26 (d, $J = 17.7$ Hz, 1H), 3.74 (d, $J = 17.7$ Hz, 1H), 3.56 (s, 3H), 3.22 (d, $J = 15.8$ Hz, 1H), 2.89 (d, $J = 15.9$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ : 195.8, 179.3, 170.5, 143.7, 136.2, 135.7, 133.9, 132.5, 130.8, 130.0, 129.7, 128.8, 128.7, 128.5, 128.5, 127.8, 127.6, 127.5, 126.9, 123.8, 123.7, 122.4, 109.4, 51.8, 47.4, 44.5, 44.5, 41.3. HRMS (APCI) m/z calcd for $\text{C}_{30}\text{H}_{26}\text{NO}_4^+$ ($\text{M}+\text{H}$) $^+$ 464.1856 , found 464.1851.




4bn

Methyl(R)-2-(1-benzyl-2-oxo-3-(2-oxo-2-(thiophen-2-yl)ethyl)indolin-3-yl)acetate (4bn): Orange oil (40 mg, 96 % yield). HPLC: 92 % ee (Chiralpak IC column, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, tr (major) = 19.681 min, tr (minor) = 16.439 min. $[\alpha]_D^{20} = +36.9$ ($c = 0.2$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ : 7.61 (d, $J = 3.9$ Hz, 1H), 7.52 (d, $J = 5.0$ Hz, 1H), 7.34 (d, $J = 7.5$ Hz, 2H), 7.28 (d, $J = 7.5$ Hz, 2H), 7.20 (d, $J = 10.0$ Hz, 2H), 7.07 (d, $J = 7.7$ Hz, 1H), 7.03–6.98 (m, 1H), 6.90–6.83 (m, 1H), 6.65 (d, $J = 7.8$ Hz, 1H), 5.04–4.82 (m, 2H), 3.88 (d, $J = 17.1$ Hz, 1H), 3.45 (s, 3H), 3.11 (d, $J = 16.0$ Hz, 1H), 2.93 (d, $J = 13.0$ Hz, 2H), 2.81 (d, $J = 16.0$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ : 188.8, 178.9, 170.3, 143.8, 143.6, 136.1, 134.1, 132.4, 130.4, 128.8, 128.5, 128.2, 127.6, 127.5, 123.9, 122.4, 109.4, 62.1, 51.8, 47.4, 44.9, 44.4, 40.9, 37.2, 34.2, 14.1. HRMS (APCI) m/z calcd for $\text{C}_{24}\text{H}_{22}\text{NO}_4\text{S}^+$ ($\text{M}+\text{H}$) $^+$ 420.1264, found 420.1258.



5a


(3R,6'R)-1-benzyl-6'-phenyl-5',6'-dihydrospiro[indoline-3,4'-pyran]-2,2'(3'H)-dione (5a): Yellow oil (31 mg, 86 % yield). dr>20:1. HPLC: 93 % ee (Chiralpak IC column, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, tr (major) = 13.245 min, tr (minor) = 10.958 min. $[\alpha]_D^{20} = +49.3$ ($c = 0.2$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ : 7.29 (d, $J = 3.9$ Hz, 6H), 7.25–7.13 (m, 6H), 7.08–7.01 (m, 1H), 6.72 (d, $J = 7.8$ Hz, 1H), 4.86 (d, $J = 15.7$ Hz, 2H), 4.63 (d, $J = 15.6$ Hz, 1H), 3.52 (d, $J = 6.2$ Hz, 1H), 3.42 (d, $J = 6.6$ Hz, 1H), 2.49 (dt, $J = 13.9, 7.0$ Hz, 1H), 2.30 (dd, $J = 14.6, 3.8$ Hz, 1H), 2.26 – 2.10 (m, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ : 181.3, 144.0, 142.4, 135.7, 132.0, 128.9, 128.4, 128.3, 127.8, 127.7, 127.4, 126.0, 123.3, 123.1, 109.7, 71.3, 58.9, 50.0, 46.6, 44.1, 39.6. HRMS (APCI) m/z calcd for $\text{C}_{25}\text{H}_{22}\text{NO}_3^+$ ($\text{M}+\text{H}$) $^+$ 384.1594, found 384.1590.



6a

Methyl(R)-2-(1-benzyl-3-(2-(5-chloro-2-(tosyloxy)phenyl)-2-oxoethyl)-2-oxoindolin-3-yl)acetate (6a): White solid (31 mg, 90 % yield). Mp 72.1–73.9 °C. HPLC: 94 %


ee (Chiralpak IC column, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, tr (major) = 14.902 min, tr (minor) = 10.833 min. $[\alpha]_D^{20} = +45.2$ ($c = 0.2$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ : 7.58 (d, $J = 8.4$ Hz, 2H), 7.45 (d, $J = 7.0$ Hz, 2H), 7.36–7.32 (m, 3H), 7.31–7.26 (m, 3H), 7.22 (d, $J = 8.1$ Hz, 2H), 7.17–7.11 (m, 2H), 6.92 (td, $J = 7.6, 1.1$ Hz, 1H), 6.72 (d, $J = 7.8$ Hz, 1H), 5.03–4.93 (m, 2H), 4.09 (d, $J = 6.7$ Hz, 1H), 3.91 (d, $J = 17.9$ Hz, 1H), 3.51 (s, 3H), 2.98 (d, $J = 15.8$ Hz, 1H), 2.81 (d, $J = 15.8$ Hz, 1H), 2.41 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ : 195.0, 170.0, 145.1, 136.1, 133.1, 132.7, 130.2, 130.1, 129.9, 128.8, 128.7, 128.5, 127.5, 124.7, 123.7, 122.4, 109.3, 51.8, 48.5, 47.3, 44.4, 41.3, 21.9, 19.3. HRMS (APCI) m/z calcd for $\text{C}_{33}\text{H}_{29}\text{ClNO}_7\text{S}^+$ ($\text{M}+\text{H}$)⁺ 618.1348, found 618.1350.




Methyl(R)-2-(1-benzyl-2-oxo-3-(2-phenylallyl)indolin-3-yl)acetate (7a): Orange oil (36 mg, 90 % yield). HPLC: 92 % ee (Chiralpak IC column, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, tr (major) = 35.729 min, tr (minor) = 13.132 min. $[\alpha]_D^{20} = +38.5$ ($c = 0.2$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ : 7.87 (d, $J = 8.2$ Hz, 2H), 7.57–7.50 (m, 1H), 7.49–7.38 (m, 4H), 7.38–7.31 (m, 3H), 7.29 (d, $J = 8.7$ Hz, 1H), 7.177.09 (m, 1H), 6.97–6.89 (m, 1H), 6.73 (d, $J = 7.8$ Hz, 1H), 5.10–4.94 (m, 2H), 4.11 (d, $J = 17.8$ Hz, 1H), 4.00 (dd, $J = 7.1, 5.5$ Hz, 2H), 3.61 (d, $J = 17.8$ Hz, 1H), 3.14 (d, $J = 15.7$ Hz, 1H), 2.83 (d, $J = 15.7$ Hz, 1H), 1.08 (t, $J = 7.1$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ : 195.9, 179.2, 169.9, 143.7, 136.6, 136.2, 133.4, 130.8, 128.8, 128.6, 128.4, 128.1, 127.6, 127.5, 123.7, 122.3, 109.4, 60.8, 47.3, 44.5, 44.4, 41.5, 41.1. HRMS (APCI) m/z calcd for $\text{C}_{27}\text{H}_{26}\text{NO}_3^+$ ($\text{M}+\text{H}$)⁺ 412.1907, found 412.1904.

VIII.NMR Spectrum


¹H NMR-**3aa** (400 MHz, CD₃Cl₃)




¹³C NMR-**3aa** (100 MHz, CD₃Cl₃)





¹H NMR-**3ab** (400 MHz, CDCl₃)



¹³C NMR-**3ab** (100 MHz, CDCl₃)




¹H NMR-**3ac** (400 MHz, CDCl₃)




¹H NMR-**3ad** (400 MHz, CDCl₃)

wxm-3-41.1. fid




¹³C NMR-**3ad** (100 MHz, CDCl₃)

wxm-3-122-ch3.2. fid




3ad


¹H NMR-**3ba** (400 MHz, CDCl₃)




¹³C NMR-**3ba** (100 MHz, CDCl₃)




¹H NMR-**3bb** (400 MHz, CDCl₃)




¹³C NMR-**3bb** (100 MHz, CDCl₃)




¹H NMR-3bc (400 MHz, CDCl₃)




¹³C NMR-**3bc** (100 MHz, CDCl₃)




¹H NMR-**3bd** (400 MHz, CDCl₃)




¹³C NMR-**3bd** (100 MHz, CDCl₃)




¹H NMR-**3be** (400 MHz, CDCl₃)




¹³C NMR-**3be** (100 MHz, CDCl₃)




¹H NMR-**3bf** (400 MHz, CDCl₃)




¹³C NMR-3bf (100 MHz, CDCl₃)



¹H NMR-**4aa** (400 MHz, CDCl₃)




¹³C NMR-**4aa** (100 MHz, CDCl₃)




¹H NMR-**4ab** (400 MHz, CDCl₃)

wxm-m-41. 1. fid




¹³C NMR-**4ab** (100 MHz, CDCl₃)

wxm-m-41. 2. fid




¹H NMR-**4ac** (400 MHz, CDCl₃)

wxm-m-4d. 1. fid




¹³C NMR-**4ac** (100 MHz, CDCl₃)


wxm-m-4d. 2. fid



¹H NMR-**4ad** (400 MHz, CDCl₃)




¹³C NMR-**4ad** (100 MHz, CDCl₃)




¹H NMR-**4ae** (400 MHz, CDCl₃)

wxm-m-4e. 1. fid




¹³C NMR-**4ae** (100 MHz, CDCl₃)

wxm-m-4e. 2. fid




¹H NMR-**4af** (400 MHz, CDCl₃)


wxm-m-41. 1. fid




wxm-m-41. 2. fid



¹H NMR-4ag (400 MHz, CDCl₃)




¹³C NMR-4ag (100 MHz, CDCl₃)





¹H NMR-4ah (400 MHz, CDCl₃)

wym-m-4.i.l.fid




¹³C NMR-4ah (100 MHz, CDCl₃)

wxm-m-4.j.2.fid




¹H NMR-4ai(400 MHz, CDCl₃)

wxm-m-4g_1.fid



¹³C NMR-4ai (100 MHz, CDCl₃)


wxm-m-4g_2_fid




¹⁹F NMR-**4ai** (376 MHz, CDCl₃)

wxm-m-4g.4. fid

—120.64





4ai




¹H NMR-**4aj** (400 MHz, CDCl₃)


wxm-m-4h.1. fid




4aj



¹³C NMR-**4aj** (100 MHz, CDCl₃)




¹H NMR-**4ak** (400 MHz, CDCl₃)




¹³C NMR-**4ak** (100 MHz, CDCl₃)

wxm-m-4c. 2. fid




¹H NMR-**4al** (400 MHz, CDCl₃)

wxm-m-4a. 1. fid




¹³C NMR-**4al** (100 MHz, CDCl₃)

wxm-m-4a.2.fid




¹H NMR-**4am** (400 MHz, CDCl₃)

wxm-m-4f.1.fid




¹³C NMR-**4am** (100 MHz, CDCl₃)

wxm-m-4f. 2. fid




¹H NMR-**4an** (400 MHz, CDCl₃)

wxm-m-4n. 1. fid




¹³C NMR-**4an** (100 MHz, CDCl₃)

wxm-m-4n.2.fid




¹⁹F NMR-**4an** (376 MHz, CDCl₃)

wxm-m-4n.4.fid




¹H NMR-**4ba** (400 MHz, CDCl₃)

wxm-m-3p. 1. fid




¹³C NMR-**4ba** (100 MHz, CDCl₃)

wxm-m-3p. 2. fid




¹H NMR-**4bb** (400 MHz, CDCl₃)

wxm-m-3a_1.fid




¹³C NMR-4bb (100 MHz, CDCl₃)

wxm-m-3q_2_fid




¹H NMR-**4bc** (400 MHz, CDCl₃)

wxm-m-3f. 1. fid




¹³C NMR-**4bc** (100 MHz, CDCl₃)

wxm-m-3f. 2. fid




¹H NMR-**4bd** (400 MHz, CDCl₃)

wxm-m-3d. 1. fid




¹³C NMR-**4bd** (100 MHz, CDCl₃)

wxm-m-3d. 2. fid




¹H NMR-4be (400 MHz, CDCl₃)

wym-m-3o_1.fid




¹³C NMR-4be (100 MHz, CDCl₃)

wxm-m-3e, 2, fid




¹H NMR-**4bf** (400 MHz, CDCl₃)

wxm-m-3t. 1. fid




wxm-m-3t. 2. fid




¹H NMR-**4bg** (400 MHz, CDCl₃)

wxm-m-3n.1.fid




¹³C NMR-**4bg** (100 MHz, CDCl₃)

wxm-m-3n.2.fid




¹H NMR-**4bh** (400 MHz, CDCl₃)


wxm-m-3n.1. fid




¹³C NMR-**4bh** (100 MHz, CDCl₃)




¹H NMR-**4bi** (400 MHz, CDCl₃)




¹³C NMR-**4bi** (100 MHz, CDCl₃)





¹H NMR-**4bj** (400 MHz, CDCl₃)




¹³C NMR-**4bj** (100 MHz, CDCl₃)



¹H NMR-**4bk** (400 MHz, CDCl₃)




¹H NMR-4bI (400 MHz, CDCl₃)




¹³C NMR-4bl (100 MHz, CDCl₃)

wxm-m-3r, 2, fid




¹H NMR-**4bm**(400 MHz, CDCl₃)

wxm-m-3s. 1. fid




¹³C NMR-**4bm** (100 MHz, CDCl₃)


wxm-m-3s. 2. fid



¹H NMR-**4bn** (400 MHz, CDCl₃)




¹³C NMR-**4bn** (100 MHz, CDCl₃)




¹H NMR-**5a** (400 MHz, CDCl₃)

wxm-m-ys-2. 1. fid




¹³C NMR-**5a** (100 MHz, CDCl₃)


wxm-m-ys-2. 2. fid




¹H NMR-**6a** (400 MHz, CDCl₃)




¹³C NMR-**6a** (100 MHz, CDCl₃)




¹H NMR-**7a** (400 MHz, CDCl₃)




¹³C NMR-**7a** (100 MHz, CDCl₃)




IX.Chiral HPLC analysis trace




racemic-3aa




chiral-3aa







racemic-3ab




chiral-3ab







3ac

racemic-3ac




chiral-3ac







3ad

racemic-3ad




chiral-3ad







racemic-3ba




chiral-3ba







racemic-3bb




chiral-3bb







racemic-3bc




chiral-3bc







3bd

racemic-3bf




chiral-3bf







3be

racemic-3be




chiral-3be







racemic-3bf




chiral-3bf







4aa

racemic-4aa




chiral-4aa







4ab

racemic-4ab




chiral-4ab







4ac

racemic-4ac




chiral-4ac







racemic-4ad




chiral-4ad







racemic-4ae




chiral-4ae







racemic-4af




chiral-4af







racemic-4ag




chiral-4ag







racemic-4ah




chiral-4ah







4ai

racemic-4ai




chiral-4ai







4aj

racemic-4aj




chiral-4aj







4ak

racemic-4ak




chiral-4ak







4al

racemic-4al




chiral-4al







4am

racemic-4am




chiral-4am







racemic-4an




chiral-4an







racemic-4ba




chiral-4ba







racemic-4bb




chiral-4bb







racemic-4bc




chiral-4bc







racemic-4bd




chiral-4bd






racemic-4be



检测器A 254nm


Peak#	Ret. Time	Area	Height	Area%
1	13.391	5693344	244630	50.257
2	19.095	5635199	158607	49.743
总计		11328543	403237	100.000

chiral-4be




Peak Table

Peak#	Ret. Time	Area	Height	Area%
1	13.412	12990866	561620	93.906
2	19.184	843014	23843	6.094
Total		13833881	585463	100.000





4bf

racemic-4bf




chiral-4bf







4bg

racemic-4bg




chiral-4bg







4bh

racemic-4bh




chiral-4bh







4bi

racemic-4bi




chiral-4bi







4bj

racemic-4bj




chiral-4bj







4bk

racemic-4bk




chiral-4bk







4bl

racemic-4bl




chiral-4bl







4bm

racemic-4bm




chiral-4bm






4bn

racemic-4bn




chiral-4bn







5a

racemic-5a




chiral-5a







6a

racemic-6a




chiral-6a






racemic-7a



Peak Table				
Peak#	Ret. Time	Area	Height	Area%
1	13.073	3767122	151865	50.071
2	35.589	3756386	51441	49.929
Total		7523508	203306	100.000

chiral-7a



Peak Table				
Peak#	Ret. Time	Area	Height	Area%
1	13.132	3707090	149781	95.968
2	35.729	155732	2350	4.032
Total		3862822	152130	100.000